Brian C. Mansfield
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Brian C. Mansfield has a total of 229 co-authors. Here are the top co-authors by number of shared publications:
- Janice Yang Chou
Section on Cellular Differentiation, Division of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA
41 shared publications Chi-Jiunn Pan
Section on Cellular Differentiation, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States of America
19 shared publicationsHyun Sik Jun
Section on Cellular Differentiation, Program on Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development and
12 shared publicationsYoung Mok Lee
Section on Cellular Differentiation, Division of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland
12 shared publications- Jun-Ho Cho
Glycogen Storage Disease Program, Department of Pediatrics, University of Connecticut School of Medicine, Farmington, Connecticut, USA
10 shared publications Lisa Zhang
Section on Cellular Differentiation, Division of Translational Medicine Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health Bethesda Maryland USA
7 shared publications
Latest Publications
- 8 December 2025
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 49 (1) , e70127
Persistent Activation of Renal Autophagy Contributes to Nephropathy in Murine Glycogen Storage Disease Type Ia
Kidney disease in glycogen storage disease type Ia (GSD‐Ia), deficient in glucose‐6‐phosphatase‐α (G6Pase‐α), is associated with acute kidney injury (AKI) and renal fibrosis. During AKI, autophagy is typically activated to eliminate protein aggregates and damaged organelles; however, sustained autophagy can contribute to maladaptive repair and fibrosis. Using a GSD‐Ia mouse model, we demonstrate that renal G6Pase‐α deficiency results in heightened autophagy activation, as indicated by increased expression of multiple autophagy‐related components and enhanced autophagic flux. Notably, both positive regulators of autophagy, including sirtuin‐1, forkhead box O3a, and AMP‐activated protein kinase, as well as the key negative regulator, mammalian target of rapamycin (mTOR), were concurrently activated in the kidneys of GSD‐Ia mice. Previous studies have shown that in response to AKI, renal levels of cyclin G1 (CG1) and cyclin‐dependent kinase 5 (CDK5) increase, promoting maladaptive dedifferentiation, G2/M cell cycle arrest in proximal tubular epithelial cells, and the formation of a TOR‐autophagy spatial coupling compartment. This sequence of events contributes to profibrotic factor production and accelerates the progression of kidney disease. In this study, we observed a significant elevation of renal CG1 and CDK5 in GSD‐Ia mice with enhanced autophagy, suggesting a potential mechanistic link to the development of renal fibrosis in GSD‐Ia. A deeper understanding of these pathways may facilitate the development of targeted therapies for GSD‐Ia nephropathy.
- 8 December 2025
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 49 (1) , e70127
Persistent Activation of Renal Autophagy Contributes to Nephropathy in Murine Glycogen Storage Disease Type Ia
Kidney disease in glycogen storage disease type Ia (GSD‐Ia), deficient in glucose‐6‐phosphatase‐α (G6Pase‐α), is associated with acute kidney injury (AKI) and renal fibrosis. During AKI, autophagy is typically activated to eliminate protein aggregates and damaged organelles; however, sustained autophagy can contribute to maladaptive repair and fibrosis. Using a GSD‐Ia mouse model, we demonstrate that renal G6Pase‐α deficiency results in heightened autophagy activation, as indicated by increased expression of multiple autophagy‐related components and enhanced autophagic flux. Notably, both positive regulators of autophagy, including sirtuin‐1, forkhead box O3a, and AMP‐activated protein kinase, as well as the key negative regulator, mammalian target of rapamycin (mTOR), were concurrently activated in the kidneys of GSD‐Ia mice. Previous studies have shown that in response to AKI, renal levels of cyclin G1 (CG1) and cyclin‐dependent kinase 5 (CDK5) increase, promoting maladaptive dedifferentiation, G2/M cell cycle arrest in proximal tubular epithelial cells, and the formation of a TOR‐autophagy spatial coupling compartment. This sequence of events contributes to profibrotic factor production and accelerates the progression of kidney disease. In this study, we observed a significant elevation of renal CG1 and CDK5 in GSD‐Ia mice with enhanced autophagy, suggesting a potential mechanistic link to the development of renal fibrosis in GSD‐Ia. A deeper understanding of these pathways may facilitate the development of targeted therapies for GSD‐Ia nephropathy.
- Open Access
- 30 May 2025
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 48 (4) , e70048
Liver‐Directed Gene Therapy Mitigates Early Nephropathy in Murine Glycogen Storage Disease Type Ia
Nephropathy is a complication of glycogen storage disease type Ia (GSD‐Ia), a metabolic disorder caused by pathogenic variants in glucose‐6‐phosphatase‐α (G6Pase‐α or G6PC1). While maintaining blood glucose homeostasis can delay the progression of renal disease in GSD‐Ia, the benefits of liver‐directed G6PC1 gene therapy on nephropathy remain unclear. This study evaluates the effects of low‐ and high‐dose G6PC1 liver gene augmentation therapy on kidney function. The G6pc−/− mice, which lack G6Pase‐α activity in both liver and kidney, were treated with G6PC1 gene therapy to restore either low or near‐normal levels of liver G6Pase‐α activity, and renal phenotype was examined at age 12 weeks. Both groups exhibited impaired renal glucose homeostasis, altered renal glucose reabsorption, acute kidney injury, and early signs of renal fibrosis. However, mice with near‐normal liver G6Pase‐α activity had better renal glucose reabsorption and homeostasis with lower serum levels of cystatin C and blood urea nitrogen, key markers of kidney function. These findings highlight the potential of liver‐directed G6PC1 gene therapy to enhance metabolic control and mitigate early kidney disease in GSD‐Ia.
- 30 May 2025
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 48 (4) , e70048
Open AccessLiver‐Directed Gene Therapy Mitigates Early Nephropathy in Murine Glycogen Storage Disease Type Ia
Nephropathy is a complication of glycogen storage disease type Ia (GSD‐Ia), a metabolic disorder caused by pathogenic variants in glucose‐6‐phosphatase‐α (G6Pase‐α or G6PC1). While maintaining blood glucose homeostasis can delay the progression of renal disease in GSD‐Ia, the benefits of liver‐directed G6PC1 gene therapy on nephropathy remain unclear. This study evaluates the effects of low‐ and high‐dose G6PC1 liver gene augmentation therapy on kidney function. The G6pc−/− mice, which lack G6Pase‐α activity in both liver and kidney, were treated with G6PC1 gene therapy to restore either low or near‐normal levels of liver G6Pase‐α activity, and renal phenotype was examined at age 12 weeks. Both groups exhibited impaired renal glucose homeostasis, altered renal glucose reabsorption, acute kidney injury, and early signs of renal fibrosis. However, mice with near‐normal liver G6Pase‐α activity had better renal glucose reabsorption and homeostasis with lower serum levels of cystatin C and blood urea nitrogen, key markers of kidney function. These findings highlight the potential of liver‐directed G6PC1 gene therapy to enhance metabolic control and mitigate early kidney disease in GSD‐Ia.
- Open Access
- 10 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
Base-editing corrects metabolic abnormalities in a humanized mouse model for glycogen storage disease type-Ia
Glycogen storage disease type-Ia patients, deficient in the G6PC1 gene encoding glucose-6-phosphatase-α, lack blood glucose control, resulting in life-threatening hypoglycemia. Here we show our humanized mouse model, huR83C, carrying the pathogenic G6PC1-R83C variant displays the phenotype of glycogen storage disease type-Ia and dies prematurely. We evaluate the efficacy of BEAM-301, a formulation of lipid nanoparticles containing a newly-engineered adenine base editor, to correct the G6PC1-R83C variant in huR83C mice and monitor phenotypic correction through one year. BEAM-301 can correct up to ~60% of the G6PC1-R83C variant in liver cells, restores blood glucose control, improves metabolic abnormalities of the disease, and confers long-term survival to the mice. Interestingly, just ~10% base correction is therapeutic. The durable pharmacological efficacy of base editing in huR83C mice supports the development of BEAM-301 as a potential therapeutic for homozygous and compound heterozygous glycogen storage disease type-Ia patients carrying the G6PC1-R83C variant.
- 10 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
Open AccessBase-editing corrects metabolic abnormalities in a humanized mouse model for glycogen storage disease type-Ia
Glycogen storage disease type-Ia patients, deficient in the G6PC1 gene encoding glucose-6-phosphatase-α, lack blood glucose control, resulting in life-threatening hypoglycemia. Here we show our humanized mouse model, huR83C, carrying the pathogenic G6PC1-R83C variant displays the phenotype of glycogen storage disease type-Ia and dies prematurely. We evaluate the efficacy of BEAM-301, a formulation of lipid nanoparticles containing a newly-engineered adenine base editor, to correct the G6PC1-R83C variant in huR83C mice and monitor phenotypic correction through one year. BEAM-301 can correct up to ~60% of the G6PC1-R83C variant in liver cells, restores blood glucose control, improves metabolic abnormalities of the disease, and confers long-term survival to the mice. Interestingly, just ~10% base correction is therapeutic. The durable pharmacological efficacy of base editing in huR83C mice supports the development of BEAM-301 as a potential therapeutic for homozygous and compound heterozygous glycogen storage disease type-Ia patients carrying the G6PC1-R83C variant.
- Open Access
- 17 April 2024
- Published by Springer Nature in Research Square
Base-editing corrects metabolic abnormalities in a humanized mouse model for glycogen storage disease type-Ia
Glycogen storage disease type-Ia (GSD-Ia) patients, deficient in glucose-6-phosphatase-α (G6Pase-α or G6PC), manifest impaired glucose homeostasis with hallmark fasting hypoglycemia. We generated a humanized knock-in mouse model, huR83C, that is homozygous for the pathogenic G6PC-R83C variant and manifests a GSD-Ia phenotype. We evaluated the efficacy of BEAM-301, lipid nanoparticles containing guide RNA and mRNA encoding a newly-engineered adenine base editor, to correct the G6PC-R83C variant in huR83C mice and monitored phenotypic correction through one year. BEAM-301-treated mice exhibited a maximum base-editing efficiency of ~60% in the liver and achieved physiologicallevels of hepatic G6Pase-α activity with just ~10% base-editing rate. The edited mice displayed an improved metabolic phenotype, sustained 24-hour fasting, and survived long-term. In contrast, untreated mice exhibited fasting hypoglycemia and died prematurely. The durable pharmacological efficacy of base editing in huR83C mice supports the development of BEAM-301 as a potential therapeutic for patients with GSD-Ia carrying the G6PC-R83C variant.
- 17 April 2024
- Published by Springer Nature in Research Square
Open AccessBase-editing corrects metabolic abnormalities in a humanized mouse model for glycogen storage disease type-Ia
Glycogen storage disease type-Ia (GSD-Ia) patients, deficient in glucose-6-phosphatase-α (G6Pase-α or G6PC), manifest impaired glucose homeostasis with hallmark fasting hypoglycemia. We generated a humanized knock-in mouse model, huR83C, that is homozygous for the pathogenic G6PC-R83C variant and manifests a GSD-Ia phenotype. We evaluated the efficacy of BEAM-301, lipid nanoparticles containing guide RNA and mRNA encoding a newly-engineered adenine base editor, to correct the G6PC-R83C variant in huR83C mice and monitored phenotypic correction through one year. BEAM-301-treated mice exhibited a maximum base-editing efficiency of ~60% in the liver and achieved physiologicallevels of hepatic G6Pase-α activity with just ~10% base-editing rate. The edited mice displayed an improved metabolic phenotype, sustained 24-hour fasting, and survived long-term. In contrast, untreated mice exhibited fasting hypoglycemia and died prematurely. The durable pharmacological efficacy of base editing in huR83C mice supports the development of BEAM-301 as a potential therapeutic for patients with GSD-Ia carrying the G6PC-R83C variant.
- Open Access
Eupatilin Improves Cilia Defects in Human CEP290 Ciliopathy Models
The photoreceptor outer segment is a highly specialized primary cilium that is essential for phototransduction and vision. Biallelic pathogenic variants in the cilia-associated gene CEP290 cause non-syndromic Leber congenital amaurosis 10 (LCA10) and syndromic diseases, where the retina is also affected. While RNA antisense oligonucleotides and gene editing are potential treatment options for the common deep intronic variant c.2991+1655A>G in CEP290, there is a need for variant-independent approaches that could be applied to a broader spectrum of ciliopathies. Here, we generated several distinct human models of CEP290-related retinal disease and investigated the effects of the flavonoid eupatilin as a potential treatment. Eupatilin improved cilium formation and length in CEP290 LCA10 patient-derived fibroblasts, in gene-edited CEP290 knockout (CEP290 KO) RPE1 cells, and in both CEP290 LCA10 and CEP290 KO iPSCs-derived retinal organoids. Furthermore, eupatilin reduced rhodopsin retention in the outer nuclear layer of CEP290 LCA10 retinal organoids. Eupatilin altered gene transcription in retinal organoids by modulating the expression of rhodopsin and by targeting cilia and synaptic plasticity pathways. This work sheds light on the mechanism of action of eupatilin and supports its potential as a variant-independent approach for CEP290-associated ciliopathies.
Open AccessEupatilin Improves Cilia Defects in Human CEP290 Ciliopathy Models
The photoreceptor outer segment is a highly specialized primary cilium that is essential for phototransduction and vision. Biallelic pathogenic variants in the cilia-associated gene CEP290 cause non-syndromic Leber congenital amaurosis 10 (LCA10) and syndromic diseases, where the retina is also affected. While RNA antisense oligonucleotides and gene editing are potential treatment options for the common deep intronic variant c.2991+1655A>G in CEP290, there is a need for variant-independent approaches that could be applied to a broader spectrum of ciliopathies. Here, we generated several distinct human models of CEP290-related retinal disease and investigated the effects of the flavonoid eupatilin as a potential treatment. Eupatilin improved cilium formation and length in CEP290 LCA10 patient-derived fibroblasts, in gene-edited CEP290 knockout (CEP290 KO) RPE1 cells, and in both CEP290 LCA10 and CEP290 KO iPSCs-derived retinal organoids. Furthermore, eupatilin reduced rhodopsin retention in the outer nuclear layer of CEP290 LCA10 retinal organoids. Eupatilin altered gene transcription in retinal organoids by modulating the expression of rhodopsin and by targeting cilia and synaptic plasticity pathways. This work sheds light on the mechanism of action of eupatilin and supports its potential as a variant-independent approach for CEP290-associated ciliopathies.
- Open Access
- 1 April 2021
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Translational Vision Science & Technology
- Vol. 10 (4) , 3
Inflammation in Viral Vector-Mediated Ocular Gene Therapy: A Review and Report From a Workshop Hosted by the Foundation Fighting Blindness, 9/2020
On September 14–15, 2020, the Foundation Fighting Blindness convened a virtual workshop to discuss intraocular inflammation during viral vector-mediated gene therapy for inherited retinal diseases. The workshop's goals were to understand immune activation's nature and significance during ocular gene therapy, consider whether ocular inflammation limits gene therapy's potential, and identify knowledge gaps for future research. The event brought together a small group of experienced researchers in the field to present and discuss current data. Collectively, participants agreed that clinical, as well as subclinical, inflammation during ocular gene therapy is common. The severity of inflammation in both animal and clinical studies varied widely but is generally related to vector dose. Severe inflammation was associated with reduced gene therapy efficacy. However, the relationship between outcomes and subclinical inflammation, pre-existing antivector antibodies, or induced adaptive immune responses is still unclear. Uncertainties about the contribution of vector manufacturing issues to inflammation were also noted. Importantly, various immunosuppressive treatment protocols are being used, and this heterogeneity confounds conclusions about optimal strategies. Proposed near-term next steps include establishing an immunological consultant directory, establishing a data repository for pertinent animal and clinical data, and developing a larger meeting. Priority areas for future research include deeper understanding of immune activation during retinal diseases and during ocular gene therapy; better, harmonized application of animal models; and identifying best practices for managing gene therapy vector-related ocular inflammation. Translational Relevance: Subclinical or clinical inflammation often arises during ocular gene therapy with viral vectors. Understanding the biological bases and impacts on efficacy are important for clinical management and the improvement of future therapies.
- 1 April 2021
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Translational Vision Science & Technology
- Vol. 10 (4) , 3
Open AccessInflammation in Viral Vector-Mediated Ocular Gene Therapy: A Review and Report From a Workshop Hosted by the Foundation Fighting Blindness, 9/2020
On September 14–15, 2020, the Foundation Fighting Blindness convened a virtual workshop to discuss intraocular inflammation during viral vector-mediated gene therapy for inherited retinal diseases. The workshop's goals were to understand immune activation's nature and significance during ocular gene therapy, consider whether ocular inflammation limits gene therapy's potential, and identify knowledge gaps for future research. The event brought together a small group of experienced researchers in the field to present and discuss current data. Collectively, participants agreed that clinical, as well as subclinical, inflammation during ocular gene therapy is common. The severity of inflammation in both animal and clinical studies varied widely but is generally related to vector dose. Severe inflammation was associated with reduced gene therapy efficacy. However, the relationship between outcomes and subclinical inflammation, pre-existing antivector antibodies, or induced adaptive immune responses is still unclear. Uncertainties about the contribution of vector manufacturing issues to inflammation were also noted. Importantly, various immunosuppressive treatment protocols are being used, and this heterogeneity confounds conclusions about optimal strategies. Proposed near-term next steps include establishing an immunological consultant directory, establishing a data repository for pertinent animal and clinical data, and developing a larger meeting. Priority areas for future research include deeper understanding of immune activation during retinal diseases and during ocular gene therapy; better, harmonized application of animal models; and identifying best practices for managing gene therapy vector-related ocular inflammation. Translational Relevance: Subclinical or clinical inflammation often arises during ocular gene therapy with viral vectors. Understanding the biological bases and impacts on efficacy are important for clinical management and the improvement of future therapies.
- Open Access
- 11 August 2020
- Published by Wiley in American Journal of Medical Genetics Part C: Seminars in Medical Genetics
- Vol. 184 (3) , 838-845
Implementation of a registry and open access genetic testing program for inherited retinal diseases within a non‐profit foundation
The Foundation Fighting Blindness is a 50‐year old 501c(3) non‐profit organization dedicated to supporting the development of treatments and cures for people affected by the inherited retinal diseases (IRD), a group of clinical diagnoses that include orphan diseases such as retinitis pigmentosa, Usher syndrome, and Stargardt disease, among others. Over $760 M has been raised and invested in preclinical and clinical research and resources. Key resources include a multi‐national clinical consortium, an international patient registry with over 15,700 members that is expanding rapidly, and an open access genetic testing program that provides no cost comprehensive genetic testing to people clinically diagnosed with an IRD living in the United States. These programs are described with particular focus on the challenges and outcomes of establishing the registry and genetic testing program.
- 11 August 2020
- Published by Wiley in American Journal of Medical Genetics Part C: Seminars in Medical Genetics
- Vol. 184 (3) , 838-845
Open AccessImplementation of a registry and open access genetic testing program for inherited retinal diseases within a non‐profit foundation
The Foundation Fighting Blindness is a 50‐year old 501c(3) non‐profit organization dedicated to supporting the development of treatments and cures for people affected by the inherited retinal diseases (IRD), a group of clinical diagnoses that include orphan diseases such as retinitis pigmentosa, Usher syndrome, and Stargardt disease, among others. Over $760 M has been raised and invested in preclinical and clinical research and resources. Key resources include a multi‐national clinical consortium, an international patient registry with over 15,700 members that is expanding rapidly, and an open access genetic testing program that provides no cost comprehensive genetic testing to people clinically diagnosed with an IRD living in the United States. These programs are described with particular focus on the challenges and outcomes of establishing the registry and genetic testing program.
- 16 May 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 527 (3) , 824-830
Gene therapy using a novel G6PC-S298C variant enhances the long-term efficacy for treating glycogen storage disease type Ia
- 16 May 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 527 (3) , 824-830
Gene therapy using a novel G6PC-S298C variant enhances the long-term efficacy for treating glycogen storage disease type Ia
- 3 February 2019
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 42 (3) , 470-479
An evolutionary approach to optimizing glucose‐6‐phosphatase‐α enzymatic activity for gene therapy of glycogen storage disease type Ia
Glycogen storage disease type‐Ia (GSD‐Ia), caused by a deficiency in glucose‐6‐phosphatase‐α (G6Pase‐α or G6PC), is characterized by impaired glucose homeostasis with a hallmark hypoglycemia, following a short fast. We have shown that G6pc‐deficient (G6pc−/−) mice treated with recombinant adeno‐associated virus (rAAV) vectors expressing either wild‐type (WT) (rAAV‐hG6PC‐WT) or codon‐optimized (co) (rAAV‐co‐hG6PC) human (h) G6Pase‐α maintain glucose homeostasis if they restore ≥3% of normal hepatic G6Pase‐α activity. The co vector, which has a higher potency, is currently being used in a phase I/II clinical trial for human GSD‐Ia (NCT 03517085). While routinely used in clinical therapies, co vectors may not always be optimal. Codon‐optimization can impact RNA secondary structure, change RNA/DNA protein‐binding sites, affect protein conformation and function, and alter posttranscriptional modifications that may reduce potency or efficacy. We therefore sought to develop alternative approaches to increase the potency of the G6PC gene transfer vectors. Using an evolutionary sequence analysis, we identified a Ser‐298 to Cys‐298 substitution naturally found in canine, mouse, rat, and several primate G6Pase‐α isozymes, that when incorporated into the WT hG6Pase‐α sequence, markedly enhanced enzymatic activity. Using G6pc−/− mice, we show that the efficacy of the rAAV‐hG6PC‐S298C vector was 3‐fold higher than that of the rAAV‐hG6PC‐WT vector. The rAAV‐hG6PC‐S298C vector with increased efficacy, that minimizes the potential problems associated with codon‐optimization, offers a valuable vector for clinical translation in human GSD‐Ia.
- 3 February 2019
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 42 (3) , 470-479
An evolutionary approach to optimizing glucose‐6‐phosphatase‐α enzymatic activity for gene therapy of glycogen storage disease type Ia
Glycogen storage disease type‐Ia (GSD‐Ia), caused by a deficiency in glucose‐6‐phosphatase‐α (G6Pase‐α or G6PC), is characterized by impaired glucose homeostasis with a hallmark hypoglycemia, following a short fast. We have shown that G6pc‐deficient (G6pc−/−) mice treated with recombinant adeno‐associated virus (rAAV) vectors expressing either wild‐type (WT) (rAAV‐hG6PC‐WT) or codon‐optimized (co) (rAAV‐co‐hG6PC) human (h) G6Pase‐α maintain glucose homeostasis if they restore ≥3% of normal hepatic G6Pase‐α activity. The co vector, which has a higher potency, is currently being used in a phase I/II clinical trial for human GSD‐Ia (NCT 03517085). While routinely used in clinical therapies, co vectors may not always be optimal. Codon‐optimization can impact RNA secondary structure, change RNA/DNA protein‐binding sites, affect protein conformation and function, and alter posttranscriptional modifications that may reduce potency or efficacy. We therefore sought to develop alternative approaches to increase the potency of the G6PC gene transfer vectors. Using an evolutionary sequence analysis, we identified a Ser‐298 to Cys‐298 substitution naturally found in canine, mouse, rat, and several primate G6Pase‐α isozymes, that when incorporated into the WT hG6Pase‐α sequence, markedly enhanced enzymatic activity. Using G6pc−/− mice, we show that the efficacy of the rAAV‐hG6PC‐S298C vector was 3‐fold higher than that of the rAAV‐hG6PC‐WT vector. The rAAV‐hG6PC‐S298C vector with increased efficacy, that minimizes the potential problems associated with codon‐optimization, offers a valuable vector for clinical translation in human GSD‐Ia.
- 14 January 2019
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 42 (3) , 459-469
Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ia at the tumor‐developing stage
Hepatocellular adenoma/carcinoma (HCA/HCC) is a long‐term complication of glycogen storage disease type‐Ia (GSD‐Ia), which is caused by a deficiency in glucose‐6‐phosphatase‐α (G6Pase‐α or G6PC), a key enzyme in gluconeogenesis. Currently, there is no therapy to address HCA/HCC in GSD‐Ia. We have previously shown that a recombinant adeno‐associated virus (rAAV) vector‐mediated G6PC gene transfer to 2‐week‐old G6pc−/− mice prevents HCA development. However, it remains unclear whether G6PC gene transfer at the tumor developing stage of GSD‐Ia can prevent tumor initiation or abrogate the pre‐existing tumors. Using liver‐specific G6pc‐knockout (L‐G6pc−/−) mice that develop HCA/HCC, we now show that treating the mice at the tumor‐developing stage with rAAV‐G6PC restores hepatic G6Pase‐α expression, normalizes glucose homeostasis, and prevents de novo HCA/HCC development. The rAAV‐G6PC treatment also normalizes defective hepatic autophagy and corrects metabolic abnormalities in the nontumor liver tissues of both tumor‐free and tumor‐bearing mice. However, gene therapy cannot restore G6Pase‐α expression in the HCA/HCC lesions and fails to abrogate any pre‐existing tumors. We show that the expression of 11 β‐hydroxysteroid dehydrogenase type‐1 that mediates local glucocorticoid activation is downregulated in HCA/HCC lesions, leading to impairment in glucocorticoid signaling critical for gluconeogenesis activation. This suggests that local glucocorticoid action downregulation in the HCA/HCC lesions may suppress gene therapy mediated G6Pase‐α restoration. Collectively, our data show that rAAV‐mediated gene therapy can prevent de novo HCA/HCC development in L‐G6pc−/− mice at the tumor developing stage, but it cannot reduce any pre‐existing tumor burden.
- 14 January 2019
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 42 (3) , 459-469
Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ia at the tumor‐developing stage
Hepatocellular adenoma/carcinoma (HCA/HCC) is a long‐term complication of glycogen storage disease type‐Ia (GSD‐Ia), which is caused by a deficiency in glucose‐6‐phosphatase‐α (G6Pase‐α or G6PC), a key enzyme in gluconeogenesis. Currently, there is no therapy to address HCA/HCC in GSD‐Ia. We have previously shown that a recombinant adeno‐associated virus (rAAV) vector‐mediated G6PC gene transfer to 2‐week‐old G6pc−/− mice prevents HCA development. However, it remains unclear whether G6PC gene transfer at the tumor developing stage of GSD‐Ia can prevent tumor initiation or abrogate the pre‐existing tumors. Using liver‐specific G6pc‐knockout (L‐G6pc−/−) mice that develop HCA/HCC, we now show that treating the mice at the tumor‐developing stage with rAAV‐G6PC restores hepatic G6Pase‐α expression, normalizes glucose homeostasis, and prevents de novo HCA/HCC development. The rAAV‐G6PC treatment also normalizes defective hepatic autophagy and corrects metabolic abnormalities in the nontumor liver tissues of both tumor‐free and tumor‐bearing mice. However, gene therapy cannot restore G6Pase‐α expression in the HCA/HCC lesions and fails to abrogate any pre‐existing tumors. We show that the expression of 11 β‐hydroxysteroid dehydrogenase type‐1 that mediates local glucocorticoid activation is downregulated in HCA/HCC lesions, leading to impairment in glucocorticoid signaling critical for gluconeogenesis activation. This suggests that local glucocorticoid action downregulation in the HCA/HCC lesions may suppress gene therapy mediated G6Pase‐α restoration. Collectively, our data show that rAAV‐mediated gene therapy can prevent de novo HCA/HCC development in L‐G6pc−/− mice at the tumor developing stage, but it cannot reduce any pre‐existing tumor burden.